This programme, featuring Prof Julian Gillmore (University College London, London, UK) and Dr Margot Davis (Vancouver General Hospital, Vancouver, CA) offers an in-depth exploration of ATTR amyloidosis, highlighting the value of observational research in understanding disease presentation, treatment patterns, and outcomes. Viewers will learn about the pathophysiology and spectrum of the condition, alongside key findings from studies presented at ESC 2025 focusing on real-world patient characteristics, therapies and outcomes. The programme concludes with expert reflections on how new evidence can inform clinical practice and future directions, supporting earlier diagnosis and more personalised approaches to care.
Your feedback helps us improve medical education and measure impact on clinical practice.
Learning Objectives
- Describe the clinical spectrum and cardiac manifestations of ATTR amyloidosis, including common phenotypes and diagnostic challenges
- Explain the significance of early diagnosis and the impact of delayed recognition on patient outcomes in ATTR amyloidosis
- Summarise the design, scope, and key real-world findings from observational studies presented at ESC 2025
- Interpret emerging epidemiological and clinical data on disease presentation, progression, and treatment patterns of ATTR amyloidosis from global real-world registries
- Apply real-world insights from these studies to optimise early identification, diagnostic evaluation, and personalised treatment strategies for patients with ATTR amyloidosis
- Discuss how integration of observational data into clinical practice can improve prognostication and long-term outcomes for patients living with ATTR amyloidosis
Target Audience
- Cardiologists
- Heart Failure Specialists
- Neurologists
- Nephrologists
- Primary Care Physicians
More from this programme
Part 1
| 1 session | |
| Highlights | Watch now |
Part 3
Part 4
| 1 session | |
| Data in Context | Watch now |
Part 5
| 1 session | |
| Translating Evidence into Practice | Watch now |
Part 6
| 1 session | |
| Key Takeaways & Closing Remarks | Watch now |
Faculty Biographies
Julian Gillmore
Prof Julian Gillmore is Professor of Medicine at University College London, London, UK. His research interests include pathogenesis, diagnosis and treatment of amyloidosis. He was appointed Centre Head at UCL’s Centre for Amyloidosis & Acute Phase Proteins in 2019 and is clinical lead for ATTR amyloidosis at the UK National Amyloidosis Centre. He has published more than 250 peer-reviewed articles, has supervised a number of students through their post-doctoral research degrees, and has received extensive grant funding.
Margot Davis
Director, University of British Columbia (UBC) Cardiology-Oncology Program, Vancouver General Hospital, Vancouver, Canada
Dr Margot Davis is a cardiologist at Vancouver General Hospital and St. Paul's Hospital, as well as the director of the UBC Cardiology-Oncology Program and a clinical assistant professor at the University of British Columbia (UBC).
Dr Davis is a key panel member of the CCS Cardio-Oncology Guidelines, a secondary panel member of the CCS Heart Failure Guidelines, and co-chair of the CCS/CHFS Position Statement on Cardiac Amyloidosis. She is vice president of the Canadian Cardiac Oncology Network and a member of the Executive Committee of the Board of Directors of the Canadian Heart Failure Society. Her research focuses on cardiac amyloidosis, severe heart failure, and cancer therapy-related heart disease prevention, diagnosis, and management.